HER-2/neu (85-94)

HER-2/neu protein: HER-2/neu (85-94) is an epitope from the extracellular region of Human Epidermal Growth Factor Receptor-2, receptor tyrosine kinase, also known as CD340, ERBB2 and proto-oncogene Neu. HER-2/neu contains a binding domain for HLA-A*02:01 molecule. It has been demonstrated that the over-expression of HER-2/neu plays an important role in the development and progression in primary breast cancer but also in ovarian colorectal and pancreatic adenocarcinoma. HER-2/neu has become an important biomarker and target of therapy for 30% of breast cancer patients. Applications of HER-2/neu (85-94): HER-2/neu (85-94) has shown its capacity to induce both cellular and humoral immune response in vivo. HER-2/neu (85-94) is used to analyze specific cytotoxic CD8 T cells responses, it has been demonstrated by ELISPOT analyses that the stimulation of cytotoxic T cells in PBMCs by HER-2/neu (85-94) produce IFN-γ against cancer cell expressing HLA-A*02:01 molecules and HER-2/neu. It has been also demonstrated that HER-2/neu (85-94) is the single peptide of HER-2/neu which involve an increase frequency of cytotoxic CD8 T cells in the peripheral blood of breast cancer patients. HER-2/neu (85-94) is also used for vaccine development to treat diagenous rat from allied ALC cancer cells co-expressing HLA-A*02:01 and HER-2/neu.